Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Study Examines Why Patients Exceed Recommended Doses of Ibuprofen & NSAIDs

Michele B. Kaufman, PharmD, BCGP  |  April 2, 2018

Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used and effective pain relievers, but they are not without risk. In the U.S., the NSAIDs ibuprofen, naproxen and aspirin are available over the counter (OTC), with the former two agents also available via prescription. In a recent study, David W. Kaufman, ScD, Slone Epidemiology Center at Boston University, and colleagues determined the prevalence of patients exceeding the daily dosing limit of NSAIDs and identified characteristics of dose-exceeding patients.1

Exceeding the daily dosing limit often resulted from taking too much of a single NSAID at once, taking different NSAIDs at the same time or failing to wait long enough before taking another dose. Experience has shown that patients often know the names of the products, but do not realize the treatments are part of the same family or have the same mechanism of action. Patients also don’t realize they should not take ibuprofen and naproxen together, or think acetaminophen is in the same class as ibuprofen, an NSAID. Additionally, combination products with NSAIDs may prevent patients from realizing that they are taking a prescription combination product of an NSAID and an OTC product together. Basically, some patients are double dosing and increasing their risk of harm.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The Research
In the study, conducted from May 2015 through March 2016, patients had to have used an ibuprofen-containing product in the preceding 30 days. Participants were not informed that the study was about NSAIDs. More than 207,000 invitations were sent out, and 4,161 people were eligible for the study based on their ibuprofen use. In total, 1,745 adults completed the seven-consecutive day online diary and the exit questionnaire, which obtained demographic information, medical history, physical and mental health status, attitudes regarding label reading and dosing behavior, and knowledge of product label instructions. Of these participants, 1,326 reported the use of ibuprofen at least once, and data from these 1,326 participants were analyzed.

Only 39% of the subjects recognized that all of the products they were taking were NSAIDs. Ninety percent of the diary users took OTC ibuprofen during the week; 37% also took non-ibuprofen NSAIDs. For ibuprofen use, 11% of users exceeded the daily dosing limit. Additionally, 4% of users of other NSAIDs exceeded the daily dosing limit. This excess occurred on 9.1% of NSAID usage days. Also, the daily limit for naproxen was exceeded by 23% of naproxen users, a higher prevalence than for ibuprofen.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Exceeding the daily dosing limit was associated with exceeding the one-time dose, particularly for individuals with one-tablet doses vs. two-tablet doses. Participant characteristics associated with exceeding the daily dosing limit were being male, having chronic or other ongoing pain, having poor physical function, having a high school level education and being a daily smoker. Additionally, these participants had the attitude of “choosing my own dose,” did not start with the lowest recommended dose and had poor knowledge of the recommended one-time and 24-hour doses. Users were more likely to exceed the one-dose medication amount, if they were in severe pain.

Page: 1 2 | Single Page
Share: 

Filed under:AnalgesicsDrug Updates Tagged with:dosageNonsteroidal anti-inflammatory drugs (NSAIDs)NSAIDsPain Management

Related Articles

    FDA to Review Abuse-Deterrent Oxycodone Capsule

    May 18, 2018

    FDA to Review Abuse-Deterrent Oxycodone Capsule In June, the FDA will discuss the New Drug Application for Remoxy ER at an Advisory Committee meeting. Remoxy ER is a 12-hour, abuse-deterrent, extended-release oxycodone in a capsule formulation.1 The capsule contains a sticky, thick, high-viscosity formulation to deter unapproved drug administration routes, including injection, smoking or snorting….

    A Comprehensive Review of NSAID Cardiovascular Toxicity

    A Comprehensive Review of NSAID Cardiovascular Toxicity

    July 18, 2018

    Non-steroidal anti-inflammatory drugs (NSAIDs) are the most used drugs for acute and chronic pain. More than 30 billion doses of NSAIDs are consumed annually from more than 70 million prescriptions.1 Despite their common use, NSAIDs are not free of serious toxicities. In the pre-Vioxx (rofecoxib) era, gastrointestinal toxicity was the primary concern for many NSAIDs….

    Celecoxib & Cardiovascular Death: NSAID Safety Under Review

    December 7, 2016

    A recent study showed that at moderate doses celecoxib may be noninferior with respect to cardiovascular safety compared with ibuprofen or naproxen…

    Rheumatology Drug Updates: Celecoxib and Cardiovascular Safety Trial Results Reviewed

    December 13, 2016

    Nonsteroidal anti-inflammatory drugs (NSAIDs) have been used therapeutically since the 1960s.1 Evidence of adverse cardiovascular outcomes led to the withdrawal of the selective COX-2 inhibitor rofecoxib in September 2004, when the question of cardiovascular safety of NSAIDs first came into the limelight.2 Valdecoxib (Bextra) was subsequently withdrawn from the market in April 2005 due to…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences